{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:20:10Z","timestamp":1788607210834,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG083883"],"award-info":[{"award-number":["R01AG083883"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG083883"],"award-info":[{"award-number":["R01AG083883"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017675","name":"William F. Vilas Trust Estate","doi-asserted-by":"publisher","award":["Early-Career Investigator Award"],"award-info":[{"award-number":["Early-Career Investigator Award"]}],"id":[{"id":"10.13039\/100017675","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017675","name":"William F. Vilas Trust Estate","doi-asserted-by":"publisher","award":["Early-Career Investigator Award"],"award-info":[{"award-number":["Early-Career Investigator Award"]}],"id":[{"id":"10.13039\/100017675","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Inflamm"],"DOI":"10.1186\/s12950-025-00455-9","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T12:35:09Z","timestamp":1752669309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Verteporfin attenuates NLRP3 inflammasome activation to alleviate gout arthritis flares"],"prefix":"10.1186","volume":"22","author":[{"given":"Daniel C.","family":"Shippy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler K.","family":"Ulland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"455_CR1","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3899\/jrheum.170806","volume":"45","author":"MM Elfishawi","year":"2018","unstructured":"Elfishawi MM, Zleik N, Kvrgic Z, Michet CJ Jr, Crowson CS, Matteson EL, Bongartz T. The Rising Incidence of Gout and the Increasing Burden of Comorbidities: A Population-based Study over 20 Years. J Rheumatol. 2018;45:574\u20139.","journal-title":"J Rheumatol"},{"key":"455_CR2","doi-asserted-by":"publisher","first-page":"15953","DOI":"10.1038\/s41598-024-61616-z","volume":"14","author":"S Punjwani","year":"2024","unstructured":"Punjwani S, Jani C, Liu W, Kakoullis L, Salciccioli I, Al Omari O, Merchant A, Singh H, Marshall D, Shalhoub J, et al. Burden of gout among different WHO regions, 1990\u20132019: estimates from the global burden of disease study. Sci Rep. 2024;14:15953.","journal-title":"Sci Rep"},{"key":"455_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrrheum.2017.155","volume":"13","author":"AK So","year":"2017","unstructured":"So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017;13:639\u201347.","journal-title":"Nat Rev Rheumatol"},{"key":"455_CR4","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","volume":"397","author":"N Dalbeth","year":"2021","unstructured":"Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout Lancet. 2021;397:1843\u201355.","journal-title":"Gout Lancet"},{"key":"455_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237\u201341.","journal-title":"Nature"},{"key":"455_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19:477\u201389.","journal-title":"Nat Rev Immunol"},{"key":"455_CR7","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1093\/rheumatology\/keu218","volume":"53","author":"LK Stamp","year":"2014","unstructured":"Stamp LK, Turner R, Khalilova IS, Zhang M, Drake J, Forbes LV, Kettle AJ. Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia. Rheumatology (Oxford). 2014;53:1958\u201365.","journal-title":"Rheumatology (Oxford)"},{"key":"455_CR8","doi-asserted-by":"crossref","unstructured":"Scott LJ, Goa KL: Verteporfin. Drugs Aging 2000, 16:139\u2013146; discussion 147\u2013138.","DOI":"10.2165\/00002512-200016020-00005"},{"key":"455_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/eye.2015.251","volume":"30","author":"DK Newman","year":"2016","unstructured":"Newman DK. Photodynamic therapy: current role in the treatment of chorioretinal conditions. Eye (Lond). 2016;30:202\u201310.","journal-title":"Eye (Lond)"},{"key":"455_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40123-020-00250-0","volume":"9","author":"EHC van Dijk","year":"2020","unstructured":"van Dijk EHC, van Rijssen TJ, Subhi Y, Boon CJF. Photodynamic Therapy for Chorioretinal Diseases: A Practical Approach. Ophthalmol Ther. 2020;9:329\u201342.","journal-title":"Ophthalmol Ther"},{"key":"455_CR11","first-page":"2326","volume":"36","author":"KR Weishaupt","year":"1976","unstructured":"Weishaupt KR, Gomer CJ, Dougherty TJ. Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. Cancer Res. 1976;36:2326\u20139.","journal-title":"Cancer Res"},{"key":"455_CR12","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.2147\/OPTH.S464371","volume":"18","author":"SJ Garg","year":"2024","unstructured":"Garg SJ, Hadziahmetovic M. Verteporfin Photodynamic Therapy for the Treatment of Chorioretinal Conditions: A Narrative Review. Clin Ophthalmol. 2024;18:1701\u201316.","journal-title":"Clin Ophthalmol"},{"key":"455_CR13","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2174\/0929867323666160316125048","volume":"23","author":"F Gibault","year":"2016","unstructured":"Gibault F, Corvaisier M, Bailly F, Huet G, Melnyk P, Cotelle P. Non-Photoinduced Biological Properties of Verteporfin. Curr Med Chem. 2016;23:1171\u201384.","journal-title":"Curr Med Chem"},{"key":"455_CR14","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1002\/jcp.26165","volume":"233","author":"V Hertig","year":"2018","unstructured":"Hertig V, Matos-Nieves A, Garg V, Villeneuve L, Mamarbachi M, Caland L, Calderone A. Nestin expression is dynamically regulated in cardiomyocytes during embryogenesis. J Cell Physiol. 2018;233:3218\u201329.","journal-title":"J Cell Physiol"},{"key":"455_CR15","doi-asserted-by":"crossref","unstructured":"Wang Y, Wang L, Wise JTF, Shi X, Chen Z: Verteporfin inhibits lipopolysaccharide-induced inflammation by multiple functions in RAW 264.7 cells. Toxicol Appl Pharmacol 2020, 387:114852.","DOI":"10.1016\/j.taap.2019.114852"},{"key":"455_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.557429","volume":"11","author":"C Wei","year":"2020","unstructured":"Wei C, Li X. The Role of Photoactivated and Non-Photoactivated Verteporfin on Tumor. Front Pharmacol. 2020;11: 557429.","journal-title":"Front Pharmacol"},{"key":"455_CR17","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/cas.13138","volume":"108","author":"H Wei","year":"2017","unstructured":"Wei H, Wang F, Wang Y, Li T, Xiu P, Zhong J, Sun X, Li J. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex. Cancer Sci. 2017;108:478\u201387.","journal-title":"Cancer Sci"},{"key":"455_CR18","doi-asserted-by":"publisher","first-page":"7602","DOI":"10.1038\/s41598-017-07632-8","volume":"7","author":"A Al-Moujahed","year":"2017","unstructured":"Al-Moujahed A, Brodowska K, Stryjewski TP, Efstathiou NE, Vasilikos I, Cichy J, Miller JW, Gragoudas E, Vavvas DG. Verteporfin inhibits growth of human glioma in vitro without light activation. Sci Rep. 2017;7:7602.","journal-title":"Sci Rep"},{"key":"455_CR19","doi-asserted-by":"publisher","first-page":"14358","DOI":"10.1038\/s41598-018-32727-1","volume":"8","author":"KL Eales","year":"2018","unstructured":"Eales KL, Wilkinson EA, Cruickshank G, Tucker JHR, Tennant DA. Verteporfin selectively kills hypoxic glioma cells through iron-binding and increased production of reactive oxygen species. Sci Rep. 2018;8:14358.","journal-title":"Sci Rep"},{"key":"455_CR20","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1111\/febs.15187","volume":"287","author":"K Kuramoto","year":"2020","unstructured":"Kuramoto K, Yamamoto M, Suzuki S, Sanomachi T, Togashi K, Seino S, Kitanaka C, Okada M. Verteporfin inhibits oxidative phosphorylation and induces cell death specifically in glioma stem cells. FEBS J. 2020;287:2023\u201336.","journal-title":"FEBS J"},{"key":"455_CR21","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1021\/acs.molpharmaceut.8b01001","volume":"16","author":"DS Pellosi","year":"2019","unstructured":"Pellosi DS, Paula LB, de Melo MT, Tedesco AC. Targeted and Synergic Glioblastoma Treatment: Multifunctional Nanoparticles Delivering Verteporfin as Adjuvant Therapy for Temozolomide Chemotherapy. Mol Pharm. 2019;16:1009\u201324.","journal-title":"Mol Pharm"},{"key":"455_CR22","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/neuonc\/noab244","volume":"24","author":"AM Barrette","year":"2022","unstructured":"Barrette AM, Ronk H, Joshi T, Mussa Z, Mehrotra M, Bouras A, Nudelman G, Jesu Raj JG, Bozec D, Lam W, et al. Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models. Neuro Oncol. 2022;24:694\u2013707.","journal-title":"Neuro Oncol"},{"key":"455_CR23","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-20-0018","volume":"27","author":"K Vigneswaran","year":"2021","unstructured":"Vigneswaran K, Boyd NH, Oh SY, Lallani S, Boucher A, Neill SG, Olson JJ, Read RD. YAP\/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma. Clin Cancer Res. 2021;27:1553\u201369.","journal-title":"Clin Cancer Res"},{"key":"455_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41\u201358.","journal-title":"Nat Rev Drug Discov"},{"key":"455_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2024.117874","volume":"112","author":"Y Tian","year":"2024","unstructured":"Tian Y, He X, Li R, Wu Y, Ren Q, Hou Y. Recent advances in the treatment of gout with NLRP3 inflammasome inhibitors. Bioorg Med Chem. 2024;112: 117874.","journal-title":"Bioorg Med Chem"},{"key":"455_CR26","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/j.celrep.2017.02.004","volume":"18","author":"EL Goldberg","year":"2017","unstructured":"Goldberg EL, Asher JL, Molony RD, Shaw AC, Zeiss CJ, Wang C, Morozova-Roche LA, Herzog RI, Iwasaki A, Dixit VD. beta-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares. Cell Rep. 2017;18:2077\u201387.","journal-title":"Cell Rep"},{"key":"455_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107375","volume":"93","author":"Y Gu","year":"2021","unstructured":"Gu Y, Zhu Y, Deng G, Liu S, Sun Y, Lv W. Curcumin analogue AI-44 alleviates MSU-induced gouty arthritis in mice via inhibiting cathepsin B-mediated NLRP3 inflammasome activation. Int Immunopharmacol. 2021;93: 107375.","journal-title":"Int Immunopharmacol"},{"key":"455_CR28","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/art.41245","volume":"72","author":"G Yang","year":"2020","unstructured":"Yang G, Lee HE, Moon SJ, Ko KM, Koh JH, Seok JK, Min JK, Heo TH, Kang HC, Cho YY, et al. Direct Binding to NLRP3 Pyrin Domain as a Novel Strategy to Prevent NLRP3-Driven Inflammation and Gouty Arthritis. Arthritis Rheumatol. 2020;72:1192\u2013202.","journal-title":"Arthritis Rheumatol"},{"key":"455_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.917056","volume":"13","author":"Y Yang","year":"2022","unstructured":"Yang Y, Xian W, Wu D, Huo Z, Hong S, Li Y, Xiao H. The role of obesity, type 2 diabetes, and metabolic factors in gout: A Mendelian randomization study. Front Endocrinol (Lausanne). 2022;13: 917056.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"455_CR30","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/annrheumdis-2016-210588","volume":"76","author":"MC Fisher","year":"2017","unstructured":"Fisher MC, Rai SK, Lu N, Zhang Y, Choi HK. The unclosing premature mortality gap in gout: a general population-based study. Ann Rheum Dis. 2017;76:1289\u201394.","journal-title":"Ann Rheum Dis"},{"key":"455_CR31","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1126\/science.7535475","volume":"267","author":"K Kuida","year":"1995","unstructured":"Kuida K, Lippke JA, Ku G, Harding MW, Livingston DJ, Su MS, Flavell RA. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science. 1995;267:2000\u20133.","journal-title":"Science"},{"key":"455_CR32","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.4049\/jimmunol.1201065","volume":"189","author":"M Kovarova","year":"2012","unstructured":"Kovarova M, Hesker PR, Jania L, Nguyen M, Snouwaert JN, Xiang Z, Lommatzsch SE, Huang MT, Ting JP, Koller BH. NLRP1-dependent pyroptosis leads to acute lung injury and morbidity in mice. J Immunol. 2012;189:2006\u201316.","journal-title":"J Immunol"},{"key":"455_CR33","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-020-01948-5","volume":"17","author":"DC Shippy","year":"2020","unstructured":"Shippy DC, Wilhelm C, Viharkumar PA, Raife TJ, Ulland TK. beta-Hydroxybutyrate inhibits inflammasome activation to attenuate Alzheimer\u2019s disease pathology. J Neuroinflammation. 2020;17:280.","journal-title":"J Neuroinflammation"},{"key":"455_CR34","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671\u20135.","journal-title":"Nat Methods"},{"key":"455_CR35","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"},{"key":"455_CR36","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.cbi.2006.09.011","volume":"164","author":"M Rasool","year":"2006","unstructured":"Rasool M, Varalakshmi P. Suppressive effect of Withania somnifera root powder on experimental gouty arthritis: An in vivo and in vitro study. Chem Biol Interact. 2006;164:174\u201380.","journal-title":"Chem Biol Interact"}],"container-title":["Journal of Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12950-025-00455-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12950-025-00455-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12950-025-00455-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T12:06:32Z","timestamp":1757246792000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal-inflammation.biomedcentral.com\/articles\/10.1186\/s12950-025-00455-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["455"],"URL":"https:\/\/doi.org\/10.1186\/s12950-025-00455-9","relation":{},"ISSN":["1476-9255"],"issn-type":[{"value":"1476-9255","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were carried out in accordance with relevant local and University of Wisconsin guidelines and regulations. All animals were handled in accordance with the Animal Research: Reporting of in vivo Experiments (ARRIVE) guidelines and the University of Wisconsin's Institutional Animal Care and Use Committee policies and our approved protocols.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}